ProKidney (PROK) News Today $3.26 +0.04 (+1.24%) Closing price 04:00 PM EasternExtended Trading$3.16 -0.09 (-2.91%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PROK Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period ProKidney Corp (PROK) Completes Re-domestication to Delaware amid Kidney Therapy AdvancementJuly 22 at 4:46 PM | msn.comMeet the Biotech Stock That Rocketed 775% HigherJuly 22 at 5:31 AM | fool.comProKidney (NASDAQ:PROK) Shares Gap Up - Here's WhyJuly 21 at 1:45 PM | marketbeat.comJP Morgan Maintains a Neutral Stance on ProKidney Corp. (PROK)July 20, 2025 | insidermonkey.comProKidney (NASDAQ:PROK) Shares Down 4.1% - Time to Sell?July 18, 2025 | marketbeat.comProKidney Corp. (NASDAQ:PROK) Receives $5.67 Average Price Target from AnalystsJuly 18, 2025 | americanbankingnews.comProKidney (NASDAQ:PROK) Trading Up 7.5% Following Analyst UpgradeJuly 16, 2025 | americanbankingnews.comProKidney (NASDAQ:PROK) Shares Gap Up on Analyst UpgradeJuly 16, 2025 | americanbankingnews.comProKidney stock soars after FDA confirms accelerated approval pathwayJuly 15, 2025 | in.investing.comProKidney Shares Surge in Early Trading On FDA Support for Kidney Drug TrialJuly 15, 2025 | marketwatch.comProKidney Shares Dip Following FDA Agreement on Rilparencel Approval StrategyJuly 15, 2025 | msn.comProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for RilparencelJuly 15, 2025 | finance.yahoo.comProKidney (NASDAQ:PROK) Trading 7.5% Higher After Analyst UpgradeJuly 15, 2025 | marketbeat.comProKidney Corp. (NASDAQ:PROK) Receives Average Recommendation of "Hold" from BrokeragesJuly 15, 2025 | marketbeat.comProKidney Corp. Announces FDA Alignment on Accelerated Approval Pathway for Rilparencel in Chronic Kidney Disease and DiabetesJuly 15, 2025 | quiverquant.comQProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for RilparencelJuly 15, 2025 | globenewswire.comProKidney (NASDAQ:PROK) Shares Gap Up Following Analyst UpgradeJuly 14, 2025 | marketbeat.comGuggenheim Increases ProKidney (NASDAQ:PROK) Price Target to $7.00July 14, 2025 | marketbeat.comProKidney Just Set a New 52-Week High. Should You Buy, Sell, or Hold PROK Stock Here?July 14, 2025 | msn.comProKidney (PROK) Gets a Sell from Bank of America SecuritiesJuly 11, 2025 | theglobeandmail.comProKidney (NASDAQ:PROK) Shares Gap Down - Should You Sell?July 11, 2025 | marketbeat.comProKidney (NASDAQ:PROK) Sees Large Volume Increase After Analyst UpgradeJuly 10, 2025 | marketbeat.comDarin J. Weber Sells 103,480 Shares of ProKidney Corp. (NASDAQ:PROK) StockJuly 10, 2025 | insidertrades.comProKidney Shares Soar After Citi Lifts Price Target to $9July 10, 2025 | msn.comRilparencel De-Risks Phase 3 As ProKidney Enters Price DiscoveryJuly 10, 2025 | seekingalpha.comProKidney Corp. (NASDAQ:PROK) Insider Darin J. Weber Sells 103,480 SharesJuly 9, 2025 | marketbeat.comTop Penny Stocks To Add to Your Watchlist - July 9thJuly 9, 2025 | marketbeat.comBiotech Stocks To Follow Today - July 9thJuly 9, 2025 | marketbeat.comProKidney (NASDAQ:PROK) Given New $9.00 Price Target at CitigroupJuly 9, 2025 | marketbeat.comProKidney (NASDAQ:PROK) Sets New 1-Year High - Here's WhyJuly 9, 2025 | marketbeat.comProKidney: What's Happening With PROK Stock?July 9, 2025 | forbes.comProKidney: Study 'Win' Send Shares Soaring >500% - New Valuation Feels FairJuly 9, 2025 | seekingalpha.comProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual ConferenceJuly 9, 2025 | globenewswire.comDow Tumbles Over 150 Points Amid Trump Tariffs: Investor Sentiment Declines, Fear Index Moves To 'Greed' ZoneJuly 9, 2025 | benzinga.comProKidney’s stock rockets on ‘intriguing’ news, but analyst doesn’t recommend buyingJuly 8, 2025 | msn.comStock Market Today: PROK Soars 515% on Surging Volume Amid Clinical Trial BuzzJuly 8, 2025 | fool.comProKidney's stock rockets on ‘intriguing' news, but analyst doesn't recommend buyingJuly 8, 2025 | marketwatch.comTop Penny Stocks Worth Watching - July 8thJuly 8, 2025 | marketbeat.comBest Small Cap Stocks To Watch Today - July 8thJuly 8, 2025 | marketbeat.comProKidney Shares Skyrocket After Favorable Results in Kidney Disease StudyJuly 8, 2025 | marketwatch.comProKidney Is Soaring on Trial Results. How Should You Play Penny Stock PROK Here?July 8, 2025 | finance.yahoo.comBest Biotech Stocks To Research - July 8thJuly 8, 2025 | marketbeat.comProKidney Shares Rise on Positive Topline Data in Rilparencel TrialJuly 8, 2025 | marketwatch.comWhy Is Penny Stock ProKidney Stock Trading Higher On Tuesday?July 8, 2025 | benzinga.comProKidney spikes after mid-stage trial data for lead assetJuly 8, 2025 | msn.comProKidney Shares Double on Strong Phase 2 Data for Kidney Disease TherapyJuly 8, 2025 | msn.comWhy Is Penny Stock ProKidney Trading Higher On Tuesday?July 8, 2025 | benzinga.comProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and DiabetesJuly 8, 2025 | globenewswire.comProKidney Insider Trading Activity | NASDAQ:PROK | BenzingaJuly 4, 2025 | benzinga.comProKidney Corp. Completes Domestication from Cayman Islands to Delaware, Retaining Nasdaq Trading Symbol "PROK"July 3, 2025 | nasdaq.com Get ProKidney News Delivered to You Automatically Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter. Email Address PROK Media Mentions By Week PROK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PROK News Sentiment▼0.770.63▲Average Medical News Sentiment PROK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PROK Articles This Week▼72▲PROK Articles Average Week Get ProKidney News Delivered to You Automatically Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VKTX News PTCT News MLTX News SWTX News PTGX News AAPG News IMVT News HCM News KYMR News CRNX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PROK) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProKidney With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
